Regeneron Pharmaceuticals Announces 84-Week Phase 3 Data for Pasatru in Adult FOP Patients
REGN Regeneron Pharmaceuticals Inc
$753.38 -1.24%
View chart & analysis → - 1Regeneron Pharmaceuticals announced 84-week results from the Phase III OPTIMA trial evaluating pasatru (garetosmab-grts) in adult FOP patients.
- 2Treatment efficacy was confirmed compared to 9 newly identified heterotopic ossification (HO) lesions in the placebo cohort between weeks 56 and 84.
- 3Professor Richard Kinch said the 84-week data shows sustained disease control along with an overall well-tolerated safety profile.
So what's the key point?
Regeneron Pharmaceuticals released trial results confirming the effectiveness of a drug for adult patients. The data showed that the drug is safe while continuing to control the disease.
Source Clinical Trials Arena · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.